




IFW

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/802,013	
	Filing Date	March 16, 2004	
	First Named Inventor	Molino	
	Group Art Unit	3617	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	5	Attorney Docket Number	2809/1331 (20011/1331)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> A copy of the Notice to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed, prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input checked="" type="checkbox"/> PTO-1449 Form (in duplicate) with 47 references (35 attached)
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 14-1138 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Alice Y. Choi Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (585) 263-1508 Fax: (585) 263-1600
Signature	 Registration No. 45,758
Date	

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____	
June 28, 2004 Date	 Signature Ruth R. Smith Typed or printed name



PATENT
Docket No.: 2809/1331

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Molino et al.)	Examiner:
)	To Be Assigned
Serial No.	:	10/802,013)	
Cnfrm. No.	:	4932)	Art Unit:
)	3617
Filed	:	March 16, 2004)	
For	:	NOVEL CYCLOSPORINS)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office ("PTO"), the enclosed references listed on the attached PTO-1449 form. Pursuant to the waiver by the PTO in 1276 Off. Gaz. Pat. Off. 55, copies of the cited U.S. patents and published U.S. patent applications are not enclosed.

Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required. If additional fees are required, however, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 14-1138.


Respectfully submitted,

Date: June 28, 2004

Alice Y. Choi
Alice Y. Choi
Registration No. 45,758

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1508
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
<u>June 28, 2004</u>	<u>Ruth R. Smith</u>
Date	Ruth R. Smith



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,013
				Filing Date	March 16, 2004
				First Named Inventor	Molino
				Art Unit	3617
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	2809/1331

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-4,639,434	01/27/1987	Wenger et al.	
	2	US-4,396,542	08/02/1983	Wenger	
	3	US-5,030,739	07/09/1991	Foricher et al.	
	4	US-5,869,709	02/09/1999	Marwah et al.	
	5	US-5,948,693	09/07/1999	Rich et al.	
	6	US-6,605,593	08/12/2003	Naicker et al.	
	7	US-6,613,729	09/02/2003	Naicker et al.	
	8	US-2002/0132763	07/17/2003	Naicker et al.	
	9	US-2003/0139326	07/24/2003	Naicker et al.	
	10	US-2003/0171264	09/11/2003	Naicker et al.	
	11	US-2003/0212249	11/13/2003	Naicker et al.	
	12	US-2003/0220234	11/27/2003	Naicker et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	13	WO	99/18120	04/15/1999	WIPO		
	14	WO	99/65933	12/23/1999	WIPO		
	15	EP	0 034 567	11/07/1984	Europe		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	Buetler et al., "Does Cyclosporin A Generate Free Radicals?" <i>TIPS</i> , 21:288-290 (2000)	
	17	Christians et al., "Cyclosporin Metabolism in Transplant Patients," <i>Pharmac. Ther.</i> , 57:291-345 (1993)	
	18	Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," <i>TIPS</i> , 5:524-527 (1984)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/802,013
				Filing Date	March 16, 2004
				First Named Inventor	Molino
				Group Art Unit	3617
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	2809/1331

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	Fritz-Langhals et al., "Synthesis of Aromatic Aldehydes by Laccase-Mediator Assisted Oxidation," <i>Tetrahedron Letters</i> , 39:5955-5956 (1998)	
	20	Henke et al., "Cyclosporine A Inhibits ATP Net Uptake of Rat Kidney Mitochondria," <i>Biochemical Pharmacology</i> , 43(5):1021-1024 (1992)	
	21	Park et al., "A Semi-Synthetic Approach to Olefinic Analogs of Amino Acid One (MeBMT) in Cyclosporin A," <i>Tetrahedron Letters</i> , 30(32):4215-4218 (1989)	
	22	Paolini, "Cyclosporin A and Free Radical Generation," <i>TRENDS in Pharmacological Sciences</i> , 22(1):14-15 (2001)	
	23	Punniyamurthy et al., "Cobalt Catalysed Allylic and Benzylic Oxidations with Dioxxygen in the Presence of Ethyl 2-Oxocyclopentanecarboxylate," <i>Tetrahedron Letters</i> , 35(23):4003-4006 (1994)	
	24	Seebach et al., "Modification of Cyclosporin A (CS): Generation of an Enolate at the Sarcosine Residue and Reactions with Electrophiles," <i>Helvetica Chimica Acta</i> , 76:1564-1590 (1993)	
	25	Seebach et al., "Thiocyclosporins: Preparation, Solution and Crystal Structure, and Immunosuppressive Activity," <i>Helvetica Chimica Acta</i> , 74:1953-1990 (1991)	
	26	Serkova et al., "The Novel Immunosuppressant SDZ-RAD Protects Rat Brain Slices from Cyclosporine-Induced Reduction of High-Energy Phosphates," <i>British Journal of Pharmacology</i> , 129:485-492 (2000)	
	27	Serino et al., "Oxygen Radical Formation by the Cytochrome P450 System as a Cellular Mechanism for Cyclosporine Toxicity," <i>Transplantation Proceedings</i> , 26:2916-2917 (1994)	
	28	Snyder et al., "Immunophilins and the Nervous System," <i>Nature Medicine</i> , 1(1):32-37 (1995)	
	29	Steiner et al., "Neurotrophic Actions of Nonimmunosuppressive Analogues of Immunosuppressive Drugs FK506, Rapamycin and Cyclosporin A," <i>Nature Medicine</i> , 3(4):421-428 (1997)	
	30	Wenger, "Structures of Cyclosporine and Its Metabolites," <i>Transplantation Proceedings</i> , 22(3):1104-1108 (1990)	
	31	Xu et al., "Redox Chemistry in Laccase-Catalyzed Oxidation of N-Hydroxy Compounds," <i>Applied and Environmental Microbiology</i> , 66(5):2052-2056 (2000)	
	32	Abel et al., "ISATX247: A Novel Calcineurin Inhibitor," <i>J. Heart Lung Transplantation</i> , 20(2):161 (2001) (abstract)	
	33	Aspeslet et al., "ISA _{TX} 247: A Novel Calcineurin Inhibitor," <i>Transplantation Proceedings</i> , 33:1048-1051 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,013
				Filing Date	March 16, 2004
				First Named Inventor	Molino
				Group Art Unit	3617
				Examiner Name	To Be Assigned
Sheet	3	of	3	Attorney Docket Number	2809/1331

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	Khanna et al., "TGF- β : A Link Between Immunosuppression, Nephrotoxicity, and CsA," <i>Transplantation Proceedings</i> , 30:944-945 (1998)	
	35	Wenger, "60. Synthesis of Cyclosporine: Total Syntheses of 'Cyclosporin A' and 'Cyclosporin H', Two Fungal Metabolites Isolated from the Species <i>Tolypocladium Inflatum</i> GAMS," <i>Helvetica Chimica Acta</i> , 67(2):502-525 (1984)	
	36	Traber, "122. Die Struktur von Cyclosporin C," <i>Helvetica Chimica Acta</i> , 60(4):1247-1255 (1977) (English Abstract Only)	
	37	Traber, "2. Neue Cyclosporine aus <i>Tolypocladium inflatum</i> Die Cyclosporine K-Z," <i>Helvetica Chimica Acta</i> , 70:13-36 (1987) (English Abstract Only)	
	38	Traber, "162. Isolierung und Strukturermittlung der neuen Cyclosporine E, F, G, H und I," <i>Helvetica Chimica Acta</i> , 65(5):1655-1677 (1982) (English Abstract Only)	
	39	Eberle et al., "Preparation of Sulfhydryl Cyclosporin A," <i>J. Org. Chem.</i> , 60:2610-2612 (1995)	
	40	Snyder et al., "Neural Actions of Immunophilin Ligands," <i>TIPS</i> , 19:21-26 (1998)	
	41	Loor, "Valspodar: Current Status and Perspectives," <i>Exp. Opin. Invest. Drugs</i> , 8(6):807-835 (1999)	
	42	Traber et al., "Cyclosporins–New Analogues by Precursor Directed Biosynthesis," <i>J. of Antibiotics</i> , 42(4):591-597 (1989)	
	43	Ko et al., "53. Solid-Phase Total Synthesis of Cyclosporine Analogues," <i>Helvetica Chimica Acta</i> , 80:695-705 (1997)	
	44	Kallen et al., "12 Cyclosporins: Recent Developments in Biosynthesis, Pharmacology and Biology, and Clinical Applications," <i>Biotechnology</i> , Second Edition, Rehm et al, eds., pp. 535-591 (1997)	
	45	Mlynar et al., "The Non-Immunosuppressive Cyclosporin A Analogue SDZ NIM 811 Inhibits Cyclophilin A Incorporation Into Virions and Virus Replication in Human Immunodeficiency Virus Type 1-Infected Primary and Growth-Arrested T Cells," <i>J. General Virology</i> , 78(4):825-835 (1997)	
	46	Loor, "Cyclosporins and Related Fungal Products in the Reversal of P-Glycoprotein-Mediated Multidrug Resistance," in <i>Multidrug Resistance in Cancer Cells</i> , Gupta et al, eds., John Wiley and Sons Ltd: Chichester, pp. 385-412 (1996)	
	47	Potthast et al., "A Novel Method for the Conversion of Benzyl Alcohols to Benzaldehydes by Laccase-Catalyzed Oxidation," <i>J. Molecular Catalysis A</i> , 108:5-9 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.